Patent ID: 8105796

Claim:
A method for screening of a pharmacologically active agent for the treatment of a HER2-positive breast cancer using (i) a polynucleotide encoding at least a portion of PI3Kβ protein or at least a portion of P110β catalytic subunit of PI3Kβ protein, or (ii) a polypeptide comprising at least a portion of PI3Kβ protein or at least a portion of p110β catalytic subunit of PI3Kβ protein; the method comprising: assaying one or more test compounds with said polynucleotide or polypeptide to select those which bind to or modulate the expression/function of PI3Kβ protein as said pharmacologically active agent, wherein said pharmacologically active agent down-regulates catalytic activity, function, stability and/or expression of PI3Kβ protein or down-regulates catalytic activity, function, stability and/or expression of p110β catalytic subunit of PI3Kβ protein; and wherein said pharmacologically active agent is a PI3Kβ inhibitor and/or antagonist.